Meridian Bioscience Aktie

Meridian Bioscience OCF-margin

Driftslikviditetsmargin for Meridian Bioscience (VIVO) pr. 20. aug. 2026 er 24,73 %. I foregående år var Driftslikviditetsmargin 21,03 % — en ændring på 17,58 % (højere).

OCF-margin

24,73 %

YoY

17,58%

Senest opdateret:

Driftslikviditetsmargin for Meridian Bioscience er 2026 24,73 % . Driftslikviditetsmargin for Meridian Bioscience var 2025 21,03 % . Det falder dermed med 17,58% højere sammenlignet med året før.
Access this data via the Eulerpool API

Meridian Bioscience Aktieanalyse

Hvad laver Meridian Bioscience? Meridian Bioscience Inc. is a global company specializing in the development, manufacture, and distribution of test kits for the diagnosis of infectious diseases and other medical conditions. The company was founded in 1976 by William J. Motto and initially focused on the development of enzyme immunoassays (EIA). Over the years, the company has grown and diversified its product offerings, becoming a leading provider of diagnostic test kits for acute and chronic medical conditions, infectious diseases, gastrointestinal infections, and virology. The company's success is attributed to its diverse range of test kits in various medical areas, including immunology, infectious diseases, sexually transmitted diseases, gastroenterology, and virology. Additionally, Meridian Bioscience Inc. stays up-to-date with the latest technological advancements in biotechnology to ensure the fast and effective performance of its tests. The company operates globally, collaborating with universities, research institutions, government agencies, and distributors to ensure the worldwide distribution and marketing of its products. In summary, Meridian Bioscience Inc. is an innovative company specializing in the development, manufacture, and distribution of test kits for the diagnosis of infectious diseases and other medical conditions. Its wide range of products, including immunology products, infectious disease diagnostics, sexually transmitted disease test kits, gastroenterology, virology, and molecular diagnostics, coupled with advanced technologies, provides fast, accurate, and reliable diagnostic support. Meridian Bioscience er et af de mest populære virksomheder på Eulerpool.com.

Hyppigt stillede spørgsmål om Meridian Bioscience aktie

Driftslikviditetsmargin for Meridian Bioscience er 24,73 % i 2026.

Driftslikviditetsmargin for Meridian Bioscience ændrede sig fra 21,03 % til 24,73 %, hvilket repræsenterer en ændring på 17,58 %. Værdien er højere end i foregående år.

På Eulerpool kan du finde den fuldstændige historiske udvikling af Driftslikviditetsmargin Meridian Bioscience siden 2006 – med årlige værdier, diagrammer og detaljeret analyse.

OCF-margin måler den procentdel af omsætningen, der konverteres til driftslikviditet. Det angiver effektiviteten af likviditetsgenerering fra kernedrift.

En 'god' varierer efter branche og virksomhedens udviklingsstadium. På Eulerpool kan du sammenligne Driftslikviditetsmargins Meridian Bioscience med konkurrenter og branchegjennemsnittet for at afgøre, om den er attraktiv.

For at evaluere Driftslikviditetsmargins er det afgørende at sammenligne det med andre virksomheder i samme branche og sektor. På Eulerpool kan du finde branchsammenligninger for Driftslikviditetsmargin.

Access this data via the Eulerpool API

Marginer — Meridian Bioscience

Alle nøgletal — Meridian Bioscience